Funding for this research was provided by:
H2020 European Research Council (#681712)
Knut och Alice Wallenbergs Stiftelse
Torsten Söderbergs Stiftelse
Received: 22 October 2019
Accepted: 2 December 2019
First Online: 13 December 2019
Ethics approval and consent to participate
: The study was approved by the Gothenburg Regional Ethical Review Board for Medical Research and was conducted in accordance with the Helsinki declaration. Oral and written informed consent was obtained from all study participants prior to enrolment.
: Not applicable.
: KB has served as a consultant or at advisory boards for Axon, Biogen, CogRx, Lilly, MagQu, Novartis and Roche Diagnostics. HZ has served at scientific advisory boards for Roche Diagnostics, Wave, Samumed and CogRx, and has given lectures in symposia sponsored by Biogen and Alzecure. KB and HZ are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. JH has served as a temporary advisory board member for Merck Sharp and Dohme, Bayer AG, Desitin GmbH, Jazz Pharmaceuticals and Itamar. He is also a co-founder and current board member of CereusScience. Olsson and Ärlig report no disclosures.